This is a request on behalf of Case Western Reserve University (CWRU)Program and its two teaching hospitals, Cleveland Metropolitan General Hospital (CMGH) and University Hospitals and Cleveland (UHC), which composes a """"""""unified primary institution"""""""" participation in the ECOG activities. During the first two years of the last grant, CMGH was the only funded institution. In July, 1987, a supplemental grant was funded to support the participation of UHC in the CWRU Program within ECOG. The supplement was in synch with year 13 and 14 of the primary grant. Since July 1, 1987 the UHC has not received any financial support from Cancer Control funds (CGOP). We are requesting continuation funding. 1. To permit the continuation of our participation in ECOG activities. 2. To develop and participate in Phase I and Phase II Protocols through the ECOG program. 3. To extend group activities of Phase III human studies. Our accrual from 5/1/85 through 4/30/88 is 641 cases with 210 cases in the past 12 months. 4. To develop scientific leadership in autologous and allogeneic bone marrow transplantation through Dr. Hillard Lazarus, who is chairman of the bone marrow transplantation committee. 5. To expand our participation in EST 5283 using autologous irradiated colon carcinoma cell vaccine with BCG in Duke's B and C colon carcinoma. 6. To promote the development of surgical activities through the P.I., a surgical oncologist. 7. To monitor the terminated adjuvant studies (EST 4276 & EST 1180) patients that will require long-term follow-up. Both are chaired by the P.I. 8. To develop Phase II-III studies in colorectal carcinoma using high-dose Leucovorin and 5-FU, based on intramural pilot studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA014548-15
Application #
3556253
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1994-04-30
Budget Start
1989-05-01
Budget End
1990-04-30
Support Year
15
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Loughran Jr, T P; Zickl, L; Olson, T L et al. (2015) Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29:886-94
Fielding, Adele K; Rowe, Jacob M; Buck, Georgina et al. (2014) UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123:843-50
Marks, David I; Moorman, Anthony V; Chilton, Lucy et al. (2013) The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica 98:945-52
Averbook, Bruce J; Lee, Sandra J; Delman, Keith A et al. (2013) Pediatric melanoma: analysis of an international registry. Cancer 119:4012-9

Showing the most recent 10 out of 59 publications